Vismodegib Improved Therapy of Medulloblastoma by Targeting Sonic Hedgehog Signaling Pathway on DAOY Medulloblastoma Cell Line
Basic and Clinical Neuroscience Journal · 01.05.2025 · 16 (3) · 609-618
DOI: 10.32598/bcn.2024.6423.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic and Clinical Neuroscience Journal, erschienen am 01.05.2025. Verfasst von Masume Behruzi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Targeting smoothened (SMO) has been a remarkable strategy for treating sonic hedgehog (Shh)-dependent cancers, especially medulloblastoma. GDC-0449, also known as vismodegib, is a potent SMO inhibitor with mild toxicity and high affinity. Thus, this study aimed to investigate the anti-medulloblastoma efficacy of vismodegib in the DAOY medulloblastoma cell line.
Methods
Human DAOY medulloblastoma cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM). 50, 80, 100, and 150 μM doses of vismodegib were used to treat cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), scratch, and trypan blue assays, as well as real-time polymerase chain reaction (RT-PCR) and immunofluorescence studies, were performed 24 and 48 h post-treatment.
Results
The MTT and trypan blue assays showed a significant difference in viability between the control and treatment groups. The results of the scratch assay showed that in the control group, the cells were able to repair the lesion, while the scratch disintegrated at higher doses of vismodegib. The expression of SMO, Gli1, and MYCN genes, the main components of the SHH signalling pathway, was significantly reduced in the vismodegib-treated groups compared to the control group. Also, a notable increase in the activation of metastasis-promoting genes (Bax and p53) and a reduction in the activation of the metastasis-inhibiting gene (Bcl2) were observed.
Conclusion
The results of the current study confirm that vismodegib is a potent inhibitor of the Shh pathway and may be used in combination with new therapeutic methods to treat medulloblastoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran.
- Department of Anatomical Sciences, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
- Department of Anatomy, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.
- Reproductive Sciences and Technology Research Center, Iran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Masume Behruzi, Mehrdad Ghorbanlou, Ronak Shabani, Auob Rustamzadeh, Enam Alhagh Gorgich, Elham Seidkhani, Farnoosh Usefi, Mehdi Mehdizadeh, Fatemeh Moradi
Zitieren
APA
Behruzi, M., Ghorbanlou, M., Shabani, R., Rustamzadeh, A., Gorgich, E. A., Seidkhani, E., Usefi, F., Mehdizadeh, M., & Moradi, F. (2025). Vismodegib Improved Therapy of Medulloblastoma by Targeting Sonic Hedgehog Signaling Pathway on DAOY Medulloblastoma Cell Line. Basic and Clinical Neuroscience Journal, 16(3), 609-618. https://doi.org/10.32598/bcn.2024.6423.1
Vancouver
Behruzi M, Ghorbanlou M, Shabani R, Rustamzadeh A, Gorgich EA, Seidkhani E, et al. Vismodegib Improved Therapy of Medulloblastoma by Targeting Sonic Hedgehog Signaling Pathway on DAOY Medulloblastoma Cell Line. Basic and Clinical Neuroscience Journal. 2025;16(3):609-618. doi:10.32598/bcn.2024.6423.1
BibTeX
@article{Behruzi2025,
author = {Behruzi, Masume and Ghorbanlou, Mehrdad and Shabani, Ronak and Rustamzadeh, Auob and Gorgich, Enam Alhagh and Seidkhani, Elham and Usefi, Farnoosh and Mehdizadeh, Mehdi and Moradi, Fatemeh},
title = {Vismodegib Improved Therapy of Medulloblastoma by Targeting Sonic Hedgehog Signaling Pathway on DAOY Medulloblastoma Cell Line},
journal = {Basic and Clinical Neuroscience Journal},
year = {2025},
volume = {16},
number = {3},
pages = {609--618},
doi = {10.32598/bcn.2024.6423.1}
}
EUVIMED